RadNet Inc. (RDNT) Touches $10.89 High on Sep, 6; Sarepta Therapeutics Has 1.52 Sentiment

September 6, 2017 - By Clifton Ray

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $2.93 billion. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. It currently has negative earnings. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

The stock of RadNet Inc. (NASDAQ:RDNT) reached all time high today, Sep, 6 and still has $11.33 target or 4.00% above today’s $10.89 share price. This indicates more upside for the $509.69 million company. This technical setup was reported by Barchart.com. If the $11.33 PT is reached, the company will be worth $20.39M more. About 499,418 shares traded or 57.50% up from the average. RadNet Inc. (NASDAQ:RDNT) has risen 53.92% since September 6, 2016 and is uptrending. It has outperformed by 37.22% the S&P500.

Among 3 analysts covering RadNet (NASDAQ:RDNT), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. RadNet has $9 highest and $700 lowest target. $8’s average target is -26.54% below currents $10.89 stock price. RadNet had 5 analyst reports since March 15, 2016 according to SRatingsIntel. The firm has “Neutral” rating by Sterne Agee CRT given on Thursday, June 2. The stock has “Buy” rating by Sidoti on Friday, April 15. The company was maintained on Tuesday, March 15 by Jefferies. The firm earned “Hold” rating on Thursday, July 13 by Jefferies. The stock of RadNet Inc. (NASDAQ:RDNT) earned “Buy” rating by Jefferies on Tuesday, August 22.

RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company has market cap of $509.69 million. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. It has a 54.05 P/E ratio. The Company’s centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders.

Venbio Select Advisor Llc holds 5.6% of its portfolio in Sarepta Therapeutics Inc for 1.01 million shares. Perceptive Advisors Llc owns 2.77 million shares or 5.41% of their US portfolio. Moreover, Sabby Management Llc has 3.21% invested in the company for 2.01 million shares. The Israel-based Sphera Funds Management Ltd. has invested 2.76% in the stock. Granite Point Capital Management L.P., a Massachusetts-based fund reported 60,000 shares.

Ratings analysis reveals 70% of Sarepta Therapeutics’s analysts are positive. Out of 10 Wall Street analysts rating Sarepta Therapeutics, 7 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $32.0 while the high is $102.0. The stock’s average target of $66.38 is 45.89% above today’s ($45.5) share price. SRPT was included in 10 notes of analysts from September 19, 2016. SunTrust upgraded the stock to “Buy” rating in Wednesday, April 5 report. On Tuesday, September 20 the stock rating was maintained by Needham with “Buy”. As per Thursday, October 27, the company rating was initiated by Morgan Stanley. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Outperform” rating given on Monday, September 19 by Robert W. Baird. The rating was initiated by JP Morgan with “Overweight” on Thursday, December 22. Wedbush maintained the shares of SRPT in report on Monday, October 10 with “Outperform” rating. RBC Capital Markets upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Monday, September 19. RBC Capital Markets has “Outperform” rating and $83.0 target. On Tuesday, October 18 the stock rating was initiated by Credit Suisse with “Outperform”. The firm has “Neutral” rating given on Tuesday, December 20 by Goldman Sachs. The firm has “Hold” rating given on Wednesday, December 14 by Jefferies.